Abstract:Mutations of mitochondrial (mt)DNA are a major cause of morbidity and mortality in humans, accounting for approximately two thirds of diagnosed mitochondrial disease. However, despite significant advances in technology since the discovery of the first disease-causing mtDNA mutations in 1988, the comprehensive diagnosis and treatment of mtDNA disease remains challenging. This is partly due to the highly variable clinical presentation linked to tissue-specific vulnerability that determines which organs are affected. Organ involvement can vary between different mtDNA mutations, and also between patients carrying the same disease-causing variant. The clinical features frequently overlap with other non-mitochondrial diseases, both rare and common, adding to the diagnostic challenge. Building on previous findings, recent technological advances have cast further light on the mechanisms which underpin the organ vulnerability in mtDNA diseases, but our understanding is far from complete. In this review we explore the origins, current knowledge, and future directions of research in this area.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **The specific origin and mechanism of mitochondrial DNA (mtDNA) diseases in different tissues and cell types**. Specifically, the article explores why certain tissues and cell types are particularly sensitive to mtDNA mutations, while other tissues and cell types show resistance or protection. Understanding this issue is crucial for explaining the diversity of clinical manifestations of mtDNA diseases and may provide a way for the development of new treatment methods. ### Overview of the main content of the paper 1. **Background introduction** - Mitochondrial DNA (mtDNA) mutations are one of the main causes of human morbidity and mortality, accounting for about two - thirds of the diagnosed mitochondrial diseases. - Although significant technological progress has been made since the first discovery of pathogenic mtDNA mutations in 1988, the comprehensive diagnosis and treatment of mtDNA diseases remain challenging. - The high variability of clinical manifestations is related to tissue - specific susceptibility, which determines which organs are affected. The organ involvement may also be different between different mtDNA mutations and among patients carrying the same pathogenic variant. 2. **Genetic bottleneck, threshold effect and differential segregation of heteroplasmic mtDNA mutations** - **Genetic bottleneck**: Most heteroplasmic mtDNA diseases are maternally inherited to the next generation because mtDNA strictly follows maternal inheritance in humans and other mammalian species. - **Threshold effect**: Studies have shown that the mutation burden is usually related to the presence of clinical symptoms, and functional defects and clinical manifestations will only appear when the mutation level exceeds a certain threshold. - **Differential segregation of heteroplasmic mtDNA mutations**: mtDNA is continuously replicated and degraded during ontogeny, and the initial burden of heteroplasmic mutations is not fixed but can change over time in tissues. 3. **Tissue - specificity of homoplasmic mtDNA diseases** - Homoplasmic mtDNA mutations (100% mutant mtDNA in all tissues) also show tissue - specific effects, indicating that in addition to the heteroplasmic burden, other factors are at work. - The most common homoplasmic mtDNA disease is Leber's hereditary optic neuropathy (LHON), which mainly affects retinal ganglion cells (RGCs) and shows incomplete penetrance. 4. **Animal model studies** - Animal models provide important tools for studying the tissue and cell specificity of mtDNA diseases, although it is challenging to generate mtDNA disease models. - By using hybrid mouse models, researchers were able to study the segregation patterns of heteroplasmic mtDNA in different tissues and reveal the role of nuclear genes (such as Gimap3) in the selection process. 5. **Single - cell and omics technologies** - The development of single - cell sequencing technology enables large - scale analysis of mtDNA dynamics in single cells, revealing the change of heteroplasmy with age and its distribution in different cell types. - The application of technologies such as high - throughput single - cell RNA sequencing (scRNAseq) has further deepened the understanding of the molecular mechanisms of mtDNA diseases. ### Summary This paper aims to deeply explore the specific origin and mechanism of mtDNA diseases in different tissues and cell types, emphasizing the importance of understanding these complex relationships for explaining disease diversity and developing new therapies. By combining genetics, biochemistry and modern omics technologies, researchers hope to be able to better explain and treat mtDNA diseases in the future.

Origins of tissue and cell-type specificity in mitochondrial DNA (mtDNA) disease

Induced Pluripotent Stem Cells: Ex Vivo Models for Human Diseases Due to Mitochondrial DNA Mutations

Advances in Mitochondrial Nucleoid Structure and Related Diseases

Patient-specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases.

Nuclear Genes and Mitochondrial Genes Associated with Mitochondrial Diseases

Therapeutic and tampering approaches for mitochondrial associated diseases

Inheritance of mitochondrial DNA in humans: implications for rare and common diseases

Mitochondrial molecular genetics and human disease

A Review over Mitochondrial Diseases Due to mtDNA Mutations: Recent Advances and Remedial Aspects

Low "penetrance" of Phylogenetic Knowledge in Mitochondrial Disease Studies.

Recurrent Tissue-Specific mtDNA Mutations Are Common in Humans

Enhanced mitochondrial genome analysis: bioinformatic and long-read sequencing advances and their diagnostic implications

Diagnostic challenges of mitochondrial DNA disorders

Mitochondrial heterogeneity in diseases

Mitochondrial diseases: the contribution of organelle stress responses to pathology

How Far Can Mitochondrial DNA Drive the Disease?

Significance of Mitochondria DNA Mutations in Diseases.

Bioinformatics Tools and Databases to Assess the Pathogenicity of Mitochondrial DNA Variants in the Field of Next Generation Sequencing

Epidemiology of Mitochondrial Disease

Single-Cell Technologies for Studying the Evolution and Function of Mitochondrial DNA Heteroplasmy in Cancer

Genetic basis of mitochondrial diseases